I am excited to announce I will be presenting at PER’s NSCLC satellite symposium during #ASCO22 in Chicago. Join us for dinner at 6:30 pm CT and then an in-depth, expert review of NSCLC treatments and clinical trials. Register now: bit.ly/3rRKJoz #LCSM #NSCLC

Kicking off #TTLC22 with a discussion of EGFR-mutant NSCLC. Great to see and discuss all the advances in the last year.

A9 We are on the way to making #lungcancer a chronic disease - seeing gains in long-term survivability and more advances to come #AskReuters #ASCO2021

A8 Débora Bruno (abstract 9005 #ASCO21 ) describes lower rates of NGS testing and clinical trial enrollment among African American versus Caucasian patients, highlighting reduced access to many of the advances that we celebrate at the annual meeting #AskReuters

A7 Progress at ASCO is always inspiring. Advances in targeted therapies, immunotherapies, and early diagnosis have helped to improve 5-year survival rates for NSCLC, up by 13% in the last five years. #AskReuters #ASCO2021

A6 Progress in #EGFR exon 20ins NSCLC – a subset lacking targeted therapy options until recently. Now FDA approval of amivantamab and emerging data for exon 20 inhibitors like DZD9008, with a response rate of 48% reported by James Yang at #ASCO2021 (Abstract 9008) #AskReuters

Exactly this - many gains to be made by effective implementation of existing advances in screening and personalized treatment for all patients. #AskReuters #ASCO2021

A2 Lung cancer screening reduces risk of dying from lung cancer, so those with a current or former history of tobacco should discuss with their doctors whether screening is right for them. This AHRQ decision aid effectivehealthcare.ahrq.gov/decision-aids/… can help with that discussion #AskReuters

Looking forward to discussing advancements in #LungCancer at #ASCO2021 with #AskReuters

Nice #lungcancer highlights from Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ - anticipated abstracts from #ASCO2021